Global Raltegravir Market 2020-2029

  • TBI579437
  • October 11, 2020
  • Global
  • 117 pages
  • QY Market Research

Introduction to Raltegravir

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. Since the beginning of the epidemic, 76 million people have been infected with the HIV virus and about 33 million people have died of HIV/AIDS. Globally, 38.0 million [31.6–44.5 million] people were living with HIV at the end of 2020. An estimated 0.7% [0.6-0.9%] of adults aged 15–49 years worldwide are living with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. The African region remains most severely affected, with nearly 1 in every 25 adults (3.7%) living with HIV and accounting for more than two-thirds of the people living with HIV worldwide. 690,000 people died of HIV-related illnesses worldwide in 2019. With nearly 160 000 people newly diagnosed with HIV, 2017 marked another year of alarming numbers of new HIV diagnoses in the WHO European Region. Encouragingly, the overall increasing trend is not as steep as before. The eastern part of the Region recorded over 130 000 new HIV diagnoses, the highest number ever. On the other hand, the European Union and European Economic Area (EU/EEA) countries reported a decline in rates of new diagnoses, mainly driven by a 20% decrease since 2015 among men who have sex with men. Despite significant advances in antiretroviral therapy (ART), which have led to dramatic decreases in patient morbidity and mortality, there remains no cure for HIV. In addition, the presence of naturally acquired and transmitted resistance to all currently available antiretroviral classes has limited available treatment options for patients living with the condition. It is estimated that as many as 18% of treatment naïve patients are resistant to at least one type of antiretroviral drug and as treatment experience progresses, as many as 76% of patients harbor viruses resistant to currently available medications. As such, there remains a need for the development of novel antiretroviral therapies that overcome current resistance patterns and treatment-related adverse events, allowing patients to remain virologically suppressed. Integrase is one of three essential HIV-1 specific enzymes encoded by the human immunodeficiency virus that catalyzes the insertion of viral double-stranded complementary DNA into the host cells' genome. Drugs that inhibit integrase block the incorporation of HIV-1 complementary DNA into the host cell, inhibiting the replication of HIV. The United States Food and Drug Association (FDA) has approved two integrase strand transfer inhibitors (ISTI), raltegravir, and elvitegravir. Raltegravir is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. Raltegravir is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Raltegravir is not a cure for HIV or AIDS. It is for use in adults and children who weigh at least 4.4 pounds (2 kilograms). This report studies the global Raltegravir market status and forecast, categorizes the global Raltegravir market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report

  • Merck Sharp & Dohme Corp.
  • Nucare Pharmaceuticals, Inc.
  • A-S Medication Solutions
  • RedPharm Drug, Inc. (U.S.A)
  • Avera McKennan Hospital
  • Cipla Ltd
  • Facmed Pharmaceuticals Pvt. Ltd
  • Jinan Chenghui-Shuangda Chemical Co., Ltd. (China)
  • Merck Frosst Canada Ltd
  • Actavis Pharma Company
  • Aphena Pharma Solutions Tennessee, Inc.
  • A-S Medication Solutions
  • Astra Zeneca
  • AstraZeneca Pharmaceuticals LP
  • Avera McKennan Hospital
  • Bryant ranch prepack
  • Cardinal Health
  • Carilion Materials Management
  • Cobalt Laboratories
  • H.J. Harkins Company
  • Lake Erie Medical & Surgical Supply Dba Quality Care Products Llc
  • Lake Erie Medical Dba Quality Care Produts Llc
  • Mantra Pharma Inc
  • Med Health Pharma LLC.
  • Mesource Pharmaceuticals
  • Nora Pharma Inc
  • PD-Rx Pharmaceuticals, Inc.
  • Pharmaris Canada Inc
  • Physicians Total Care, Inc.
  • Pro Doc Limitee
  • Qd Pharmaceuticals Ulc
  • Ranbaxy Inc.
  • Rebel Distributors
  • Remedy Repack
  • Sanis Health Inc
  • Sivem Pharmaceuticals Ulc
  • Sun Pharmaceutical Industries, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

  • Tablet
  • Oral powder

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share, and growth rate for each application, including

  • Hospital
  • Drug store
  • Others

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering

  • North America
  • Europe
  • China
  • Japan
  • Southeast Asia
  • India

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

  • United States
  • Canada
  • Mexico


  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Singapore
  • Rest of Asia-Pacific


  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Central & South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East & Africa

  • Saudi Arabia
  • Turkey
  • Rest of Middle East & Africa

The study objectives of this report are:

To analyze and study the global Raltegravir capacity, production, value, consumption, status (2013-2017) and forecast (2020-2029); Focuses on the key Raltegravir manufacturers, to study the capacity, production, value, market share, and development plans in the future. Focuses on the global key manufacturers, to define, describe, and analyze the market competition landscape, SWOT analysis. To define, describe, and forecast the market by type, application, and region. To analyze the global and key regions' market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends and factors driving or inhibiting market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To strategically analyze each submarket with respect to individual growth trend and their contribution to the market To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Raltegravir are as follows: History Year: 2014-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

  • Key Stakeholders
  • Raltegravir Manufacturers
  • Raltegravir Distributors/Traders/Wholesalers
  • Raltegravir Subcomponent Manufacturers
  • Industry Association
  • Downstream Vendors

Table of Contents

Global Raltegravir Market Research Report 2018
1 Raltegravir Market Overview
    1.1 Product Overview and Scope of Raltegravir
    1.2 Raltegravir Segment by Type (Product Category)
        1.2.1 Global Raltegravir Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
        1.2.2 Global Raltegravir Production Market Share by Type (Product Category) in 2017
        1.2.3 Tablet
        1.2.3 Oral powder
    1.3 Global Raltegravir Segment by Application
        1.3.1 Raltegravir Consumption (Sales) Comparison by Application (2013-2025)
        1.3.2 Hospital
        1.3.3 Drug store
        1.3.4 Others
    1.4 Global Raltegravir Market by Region (2013-2025)
        1.4.1 Global Raltegravir Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
        1.4.2 North America Status and Prospect (2013-2025)
        1.4.3 Europe Status and Prospect (2013-2025)
        1.4.4 China Status and Prospect (2013-2025)
        1.4.5 Japan Status and Prospect (2013-2025)
        1.4.6 Southeast Asia Status and Prospect (2013-2025)
        1.4.7 India Status and Prospect (2013-2025)
    1.5 Global Market Size (Value) of Raltegravir (2013-2025)
        1.5.1 Global Raltegravir Revenue Status and Outlook (2013-2025)
        1.5.2 Global Raltegravir Capacity, Production Status and Outlook (2013-2025)

2 Global Raltegravir Market Competition by Manufacturers
    2.1 Global Raltegravir Capacity, Production and Share by Manufacturers (2013-2018)
        2.1.1 Global Raltegravir Capacity and Share by Manufacturers (2013-2018)
        2.1.2 Global Raltegravir Production and Share by Manufacturers (2013-2018)
    2.2 Global Raltegravir Revenue and Share by Manufacturers (2013-2018)
    2.3 Global Raltegravir Average Price by Manufacturers (2013-2018)
    2.4 Manufacturers Raltegravir Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Raltegravir Market Competitive Situation and Trends
        2.5.1 Raltegravir Market Concentration Rate
        2.5.2 Raltegravir Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Raltegravir Capacity, Production, Revenue (Value) by Region (2013-2018)
    3.1 Global Raltegravir Capacity and Market ...
| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form